27 January 2026 : Original article
Long-Term Patency of Hemashield Vascular Grafts Used for Middle Hepatic Vein Reconstruction During Living-Donor Liver Transplantation: A Single-Center Korean Experience
Dae Hyeon Won
BCE 1, Shin Hwang ACDEF 1*, Chul-Soo Ahn BCD 1, Deok-Bog Moon BCD 1, Tae-Yong Ha ABCD 1, Gi-Won Song BCD 1, Dong-Hwan Jung BCD 1, Gil-Chun Park BCD 1, Woo-Hyoung Kang BCD 1, Young-In Yoon BCD 1, Sung-Gyu Lee ABCD 1
DOI: 10.12659/AOT.951216
Ann Transplant 2026; 31:e951216
Table 1 Clinical profiles of patients who underwent middle hepatic vein reconstruction using Hemashield vascular grafts.
| Parameters | Values |
|---|---|
| Patients (n) | 149 |
| Age (years) | 56.2±7.7 |
| Sex (n) | |
| Male | 111 (74.5%) |
| Female | 38 (25.5%) |
| MELD score | 15.2±8.6 |
| Underlying liver disease (n) | |
| HBV infection | 76 (51.0%) |
| HCV infection | 6 (4.0%) |
| Alcoholic liver disease | 48 (32.2%) |
| Others | 19 (12.8%) |
| Concurrent hepatocellular carcinoma (n) | 77 (51.7%) |
| ABO-incompatible transplantation (n) | 37 (24.8%) |
| Graft-to-recipient weight ratio | 1.06±0.25 |
| MELD – Model for End-stage Liver Disease; HBV – hepatitis B virus; HCV – hepatitis C virus. | |